PKO Investment Management Joint Stock Co Purchases 3,000 Shares of Boston Scientific Corporation (NYSE:BSX)

PKO Investment Management Joint Stock Co lifted its position in Boston Scientific Corporation (NYSE:BSX - Free Report) by 30.0% during the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 13,000 shares of the medical equipment provider's stock after purchasing an additional 3,000 shares during the period. PKO Investment Management Joint Stock Co's holdings in Boston Scientific were worth $1,311,000 as of its most recent SEC filing.

Several other hedge funds also recently made changes to their positions in the company. Vanguard Group Inc. grew its holdings in Boston Scientific by 1.2% in the 4th quarter. Vanguard Group Inc. now owns 132,890,784 shares of the medical equipment provider's stock worth $11,869,805,000 after acquiring an additional 1,600,062 shares during the last quarter. Wellington Management Group LLP boosted its holdings in shares of Boston Scientific by 10.2% during the fourth quarter. Wellington Management Group LLP now owns 36,165,399 shares of the medical equipment provider's stock worth $3,230,293,000 after purchasing an additional 3,344,571 shares during the period. Geode Capital Management LLC grew its stake in shares of Boston Scientific by 3.5% in the fourth quarter. Geode Capital Management LLC now owns 30,626,170 shares of the medical equipment provider's stock worth $2,729,371,000 after purchasing an additional 1,041,329 shares during the last quarter. Capital World Investors increased its holdings in Boston Scientific by 28.7% during the 4th quarter. Capital World Investors now owns 27,899,903 shares of the medical equipment provider's stock valued at $2,492,041,000 after purchasing an additional 6,216,199 shares during the period. Finally, DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main raised its position in Boston Scientific by 2.5% during the 4th quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 22,312,967 shares of the medical equipment provider's stock valued at $1,992,994,000 after purchasing an additional 554,388 shares during the last quarter. 89.07% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

BSX has been the topic of a number of recent analyst reports. Royal Bank Of Canada lifted their price objective on Boston Scientific from $116.00 to $120.00 and gave the stock an "outperform" rating in a research report on Thursday, April 24th. Morgan Stanley lifted their price target on shares of Boston Scientific from $120.00 to $125.00 and gave the company an "overweight" rating in a report on Friday, May 16th. Citigroup restated a "buy" rating and issued a $125.00 price objective (up from $119.00) on shares of Boston Scientific in a report on Thursday, May 22nd. Leerink Partners initiated coverage on shares of Boston Scientific in a research note on Monday. They set an "outperform" rating and a $118.00 target price on the stock. Finally, Truist Financial boosted their price target on shares of Boston Scientific from $113.00 to $117.00 and gave the company a "buy" rating in a research report on Thursday, April 24th. Twenty-two investment analysts have rated the stock with a buy rating and three have assigned a strong buy rating to the stock. According to data from MarketBeat, Boston Scientific presently has a consensus rating of "Buy" and an average price target of $116.09.

Insider Transactions at Boston Scientific

In other Boston Scientific news, SVP Vance R. Brown sold 4,826 shares of the stock in a transaction on Monday, April 21st. The stock was sold at an average price of $95.09, for a total transaction of $458,904.34. Following the sale, the senior vice president now directly owns 36,193 shares in the company, valued at approximately $3,441,592.37. This trade represents a 11.77% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Arthur C. Butcher sold 17,314 shares of the business's stock in a transaction on Thursday, May 1st. The stock was sold at an average price of $102.06, for a total value of $1,767,066.84. Following the completion of the transaction, the executive vice president now owns 22,235 shares of the company's stock, valued at $2,269,304.10. This represents a 43.78% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 411,970 shares of company stock worth $42,406,693. Corporate insiders own 0.50% of the company's stock.

Boston Scientific Stock Down 0.4%

BSX stock traded down $0.37 on Thursday, reaching $101.36. 5,188,625 shares of the company traded hands, compared to its average volume of 6,586,240. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.45 and a quick ratio of 0.88. The firm has a fifty day simple moving average of $101.44 and a 200-day simple moving average of $98.91. Boston Scientific Corporation has a one year low of $71.88 and a one year high of $107.17. The company has a market cap of $149.96 billion, a P/E ratio of 73.99, a price-to-earnings-growth ratio of 2.63 and a beta of 0.68.

Boston Scientific (NYSE:BSX - Get Free Report) last issued its quarterly earnings results on Wednesday, April 23rd. The medical equipment provider reported $0.75 earnings per share for the quarter, beating the consensus estimate of $0.67 by $0.08. The firm had revenue of $4.66 billion during the quarter, compared to the consensus estimate of $4.57 billion. Boston Scientific had a return on equity of 18.67% and a net margin of 11.58%. The company's revenue was up 20.9% on a year-over-year basis. During the same period last year, the company earned $0.56 earnings per share. Research analysts anticipate that Boston Scientific Corporation will post 2.85 earnings per share for the current year.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.